Table 3.
Multivariate results of potential confounders of compliance
| McFadden’s R2=0.029 | Compliance
|
|||||
|---|---|---|---|---|---|---|
| Without active substance
|
Controlling for active substances
|
|||||
| Percentage points | Odds ratio | 95% CI | Percentage points | Odds ratio | 95% CI | |
| Explanatory variables | ||||||
| Medical device DPI | −6.46* | 0.69* | (0.575–0.841) | −4.48** | 0.77** | (0.617–0.972) |
| ICS/LABA | ||||||
| Formoterol/budesonide | – | – | – | 1.02 | 1.065 | (0.830–1.368) |
| Salmeterol/fluticasone | – | – | – | 5.78** | 1.398** | (1.104–1.770) |
| Severity | ||||||
| Persistent mild | 11.02* | 2.22* | (1.737–2.834) | 10.81* | 2.188* | (1.712–2.796) |
| Persistent moderate | 15.42* | 2.82* | (2.203–3.610) | 15.26* | 2.791* | (2.180–3.575) |
| Persistent severe | 24.08* | 4.26* | (1.994–9.124) | 24.41* | 4.322* | (2.017–9.260) |
| Therapy line | ||||||
| Second | 14.04* | 2.10* | (1.558–2.831) | 13.69* | 2.07* | (1.535–2.791) |
| Third | 65.53* | 29.0* | (9.794–85.92) | 65.20* | 28.43* | (9.575–84.45) |
| Age | 0.13 | 1.008 | (0.999–1.016) | 0.12 | 1.007 | (0.999–1.015) |
| Retired | 2.96 | 1.188 | (0.843–1.597) | 2.97 | 1.190 | (0.885–1.601) |
| Smoker | −1.74 | 0.902 | (0.733–1.109) | −1.87 | 0.894 | (0.727–1.100) |
| Hypertension | −0.95 | 0.946 | (0.748–1.194) | −0.95 | 0.945 | (0.748–1.194) |
| Organ failures | 3.06 | 1.195 | (0.896–1.595) | 2.93 | 1.187 | (0.889–1.585) |
| Allergy | 3.70** | 1.24** | (1.045–1.474) | 3.96** | 1.261** | (1.061–1.497) |
| Acute exacerbations | −8.02* | 0.626* | (0.417–0.938) | −8.61** | 0.604** | (0.402–0.907) |
| Mild/moderate exacerbations | 0.67 | 1.040 | (0.868–1.245) | 0.746 | 1.04 | (0.871–1.252) |
| Pharmacological cost | −0.170* | 0.988* | (0.986–0.992) | −0.179* | 0.989* | (0.986–0.992) |
| Visit to GP | 0.04 | 1.002 | (0.995–1.009) | 0.04* | 1.002* | (0.995–1.009) |
Notes:
*
P<0.001,
**
P<0.05.
Abbreviations: CI, confidence interval; DPI, dry powder inhaler; GP, general practitioner; ICS/LABA, inhaled corticosteroid and long-acting β2-agonist; pMDI, pressurized metered dose inhaler; –, not considered within the regression.